National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

anti-endoglin monoclonal antibody TRC105
A human/murine chimeric monoclonal antibody directed against endoglin (CD105) with potential antiangiogenic and antineoplastic activities. Anti-endoglin monoclonal antibody TRC105 binds to endoglin, which may result in inhibition of tumor angiogenesis and decreased tumor cell proliferation. The glycoprotein endoglin is a transforming growth factor beta-1 (TGF beta-1) accessory receptor that is highly expressed on tumor vessel endothelial cells and appears to be essential for angiogenesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:TRC105



Previous:anti-CS1 monoclonal antibody HuLuc63, anti-denatured collagen recombinant monoclonal antibody TRC093, anti-DR5 agonist monoclonal antibody TRA-8, anti-EGFR monoclonal antibody RO5083945, anti-EGFRvIII vaccine CDX-110
Next:anti-EpCAM antibody fragment -Pseudomonas exotoxin fusion protein, anti-EpCAM antibody fragment-bouganin fusion protein, anti-EpCAM/anti-CD3 recombinant bispecific monoclonal antibody MT110, anti-ErbB3 receptor monoclonal antibody MM-121, anti-FLT-1 ribozyme

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov